ASPIC

The therapeutic landscape in breast cancer has benefited from the development of variate antibody-based therapies. Yet, pre-clinical models capable of recapitulating the complex crosstalk within the tumor microenvironment (TME) are needed to properly address the effect of such therapies. In this work, we devised cell models able to accommodate different cell populations (3D-3), by adding stromal and immune components to multicellular tumor spheroids. The models were microencapsulated in alginate and kept under stirred conditions, to recreate critical hallmarks of the TME.

With the approval of the first Immune-Checkpoint Inhibitor (ICI), a new category of side effects has emerged - immune-related adverse events. ICI-related pneumonitis is a rare, but potentially fatal side effect, with an incidence of 3–10% in different trials involving ICI, with greater incidence in patients with non-small cell lung cancer (NSCLC). This is the largest histopathologic study to date (n = 16) characterizing non-neoplastic lung tissue from ICI-treated patients, in mono- or polytherapy regimens.

Authors and Affiliations:

Authors and Affiliations:
Rita F. Oliveira ^1,2, Ana I. Oliveira ¹, Agostinho Cruz ¹, Oscar Ribeiro ², Vera Afreixo ³ and Francisco Pimentel ⁴

¹ REQUIMTE/LAQV, ESS, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida 400, 4200-072 Porto, Portugal

Authors and Affiliations:

Diana Luísa Almeida-Nunes ^1,2,3, João P. N. Silva ⁴, Mariana Nunes ^3,5, Patrícia M. A. Silva ^1,4,6, Ricardo Silvestre ^7,8, Ricardo Jorge Dinis-Oliveira ^1,6,9,10, Hassan Bousbaa ⁴ and Sara Ricardo ^1,2,3,4,

¹ Associate Laboratory i4HB—Institute for Health and Bioeconomy, University Institute of Health Sciences—CESPU, 4585-116 Gandra, Portugal.

Investigadores do Instituto Universitário de Ciências da Saúde – CESPU e da Unidade de Biociências Moleculares Aplicadas (UCIBIO) em colaboração com investigadores do Instituto de Investigação e Inovação em Saúde da Universidade do Porto (i3S) e Instituto de Investigação em Ciências da Vida e da Saúde (ICVS) descobriram que a metformina reduz o efeito anti-tumoral do linsitinib no contexto do cancro de ovário.

Venous thromboembolism (VTE) affects up to 20% of cancer patients, presenting a risk four to seven times higher than that of the general population. This elevated risk is attributed to factors related to the patient, the tumour, and treatments. When deciding on primary thromboprophylaxis, these factors, along with the potential for bleeding and the impact on the patient’s quality of life, are considered.

O tromboembolismo venoso (TEV) afeta até 20% dos doentes com cancro, apresentando um risco quatro a sete vezes superior ao da população geral. Este risco elevado é atribuído a fatores relacionados com o paciente, tumor e tratamentos. Na decisão sobre a tromboprofilaxia primária, estes fatores, juntamente com o potencial para hemorragia e impacto na qualidade de vida do paciente, são considerados.